From Lead Compounds to Potential Therapeutics: Drugs to Treat Clostridium Difficile Infections

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/GNT1124032

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Clostridium difficile infection (CDI) attacks the gut resulting in diarrhoea and inflammation of the colon. It is classified as the number one antibiotic-resistant bacterial threat in the USA where there are 500,000 cases of CDI and 30,000 deaths. CDI is an increasing problem for hospitalized patients in the US, the EU and Australia. Our recent NHMRC funded project established drug leads against CDI and we now require continued studies to develop our drug leads towards marketable therapeutics.

Funded Activity Details

Start Date: 01-01-2017

End Date: 01-01-2020

Funding Scheme: Project Grants

Funding Amount: $523,460.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Biologically Active Molecules

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

antibiotic resistance | antibiotic therapy | antimicrobial therapy | drug development | microbial infections

Related Links